Overview
NICE is unable to make a recommendation on ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma in adults who have had sorafenib, because Lilly did not provide an evidence submission.
Last reviewed: 30 October 2019
Next review: We will review this decision if the company decides to make a submission.